An AI to accelerate bladder cancer diagnosis


Despite its importance, early diagnosis of certain pathologies presents difficulties. Researchers from the ISMO1Institut des Sciences Moléculaires d’Orsay (CNRS/Université Paris-Sud) and the Bicêtre University Hospital in Paris have looked into fluorescent imaging for the early detection of bladder cancer. The VitaDX start-up company is pursuing these landmark studies to develop, in collaboration with the French national aerospace research center ONERA and the Paris-Saclay technology transfer company, an artificial intelligence tool that can automatically distinguish healthy from cancerous cells in a fluorescent signature. The VisioCyt software should be marketed in early 2020.